Lanean...
1600. Closing the gap on moxifloxacin breakpoints for Stenotrophomonas maltophilia
BACKGROUND: Moxifloxacin (MOX) has in vitro activity against Enterobacterales and Stenotrophomonas maltophilia (SM). Although MOX commonly displays lower minimum inhibitory concentration (MIC)(50/90) values against SM when compared to levofloxacin, there are currently no established MOX breakpoints...
Gorde:
| Argitaratua izan da: | Open Forum Infect Dis |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7776320/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1780 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|